Article (Scientific journals)
Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease.
Fröhlich, Holger; Bontridder, Noémi; Petrovska-Delacréta, Dijana et al.
2022In Frontiers in Neurology, 13, p. 788427
Peer Reviewed verified by ORBi
 

Files


Full Text
fneur-13-788427 (1).pdf
Publisher postprint (539.05 kB)
Download

The original publication is available at https://doi.org/10.3389/fneur.2022.788427


All documents in ORBilu are protected by a user license.

Send to



Details



Keywords :
Artificial Intelligence; Parkinson's Disease; digital biomarker; digital health; precision medicine
Abstract :
[en] Recent years have witnessed a strongly increasing interest in digital technology within medicine (sensor devices, specific smartphone apps) and specifically also neurology. Quantitative measures derived from digital technology could provide Digital Biomarkers (DMs) enabling a quantitative and continuous monitoring of disease symptoms, also outside clinics. This includes the possibility to continuously and sensitively monitor the response to treatment, hence opening the opportunity to adapt medication pathways quickly. In addition, DMs may in the future allow early diagnosis, stratification of patient subgroups and prediction of clinical outcomes. Thus, DMs could complement or in certain cases even replace classical examiner-based outcome measures and molecular biomarkers measured in cerebral spinal fluid, blood, urine, saliva, or other body liquids. Altogether, DMs could play a prominent role in the emerging field of precision medicine. However, realizing this vision requires dedicated research. First, advanced data analytical methods need to be developed and applied, which extract candidate DMs from raw signals. Second, these candidate DMs need to be validated by (a) showing their correlation to established clinical outcome measures, and (b) demonstrating their diagnostic and/or prognostic value compared to established biomarkers. These points again require the use of advanced data analytical methods, including machine learning. In addition, the arising ethical, legal and social questions associated with the collection and processing of sensitive patient data and the use of machine learning methods to analyze these data for better individualized treatment of the disease, must be considered thoroughly. Using Parkinson's Disease (PD) as a prime example of a complex multifactorial disorder, the purpose of this article is to critically review the current state of research regarding the use of DMs, discuss open challenges and highlight emerging new directions.
Research center :
- Luxembourg Centre for Systems Biomedicine (LCSB): Biomedical Data Science (Glaab Group)
Disciplines :
Life sciences: Multidisciplinary, general & others
Biotechnology
Neurology
Author, co-author :
Fröhlich, Holger
Bontridder, Noémi
Petrovska-Delacréta, Dijana
Glaab, Enrico  ;  University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Biomedical Data Science
Kluge, Felix
Yacoubi, Mounim El
Marín Valero, Mayca
Corvol, Jean-Christophe
Eskofier, Bjoern
Van Gyseghem, Jean-Marc
Lehericy, Stepháne
Winkler, Jürgen
Klucken, Jochen
More authors (3 more) Less
External co-authors :
yes
Language :
English
Title :
Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease.
Publication date :
2022
Journal title :
Frontiers in Neurology
ISSN :
1664-2295
Publisher :
Frontiers Media S.A., Switzerland
Volume :
13
Pages :
788427
Peer reviewed :
Peer Reviewed verified by ORBi
Focus Area :
Systems Biomedicine
FnR Project :
FNR14599012 - Validating Digital Biomarkers For Better Personalized Treatment Of Parkinson'S Disease, 2020 (01/05/2021-30/04/2024) - Enrico Glaab
Name of the research project :
DIGIPD
Funders :
FNR - Fonds National de la Recherche [LU]
Available on ORBilu :
since 30 March 2022

Statistics


Number of views
103 (2 by Unilu)
Number of downloads
52 (0 by Unilu)

OpenCitations
 
2
WoS citations
 
5

Bibliography


Similar publications



Contact ORBilu